The Scalpel’s New Rival: Incretins Now Match Surgery

Key Takeaway: A comprehensive review of 38 randomized trials involving over 25,000 adults confirms that next-generation incretin-based weight loss medications can reduce body weight by up to 24%, rivaling outcomes historically achievable only through bariatric surgery. While gastrointestinal side effects remain common, the rarity of serious adverse events solidifies the position of these drugs as a cornerstone of modern obesity treatment.

Surgical Outcomes Without the Scalpel

For decades, the gold standard for significant, lasting weight loss has been bariatric surgery, with procedures like gastric bypass and sleeve gastrectomy capable of producing a 25–30% reduction in body weight^[2]. But surgery carries its own risks: general anesthesia, hospitalization, nutritional deficiencies, and the occasional need for revision. Therefore, the emergence of an injectable class of drugs delivering results that overlap with these surgical thresholds holds enormous implications for the millions of people living with obesity. A major new analysis of 38 clinical trials confirms this is no longer a theoretical promise; it is happening in real-time, in thousands of patients, with a reassuring safety profile.

Study Scope and Methodology

This updated systematic review pooled data from 38 randomized controlled trials involving a total of 25,816 adults without diabetes who were treated with GLP-1 receptor agonists (GLP-1 RAs) or newer multi-agonist compounds for weight management. The review compared the percentage of body weight loss after subtracting the change observed in the placebo group—a critical step, as participants receiving placebo in obesity studies often lose a few points of body weight through lifestyle changes alone. The analysis included established agents like subcutaneous semaglutide and tirzepatide, as well as emerging compounds still in clinical development, such as amycretin and retatrutide.

Key Findings

The results are striking. Placebo-subtracted weight loss reached 14.8% for subcutaneous semaglutide, the active ingredient in Wegovy, and 19.0% for the dual agonist tirzepatide, marketed for weight management as Zepbound^[1]. But the multi-agonist drugs in development raised the bar even higher: placebo-subtracted weight loss of 23.9% was achieved with amycretin, and 22.1% with retatrutide. These figures move pharmacotherapy squarely into territory once exclusive to the operating room.

From a safety perspective, gastrointestinal adverse events like nausea, vomiting, diarrhea, and constipation were common, occurring in 76.0% of the active drug group compared to 40.1% in the placebo group. These side effects are familiar to anyone who prescribes or uses these medications and are typically most pronounced during dose escalation. Critically, serious adverse events were rare: 6.5% in the treatment groups versus 5.2% in the placebo group, with no new safety signals detected across the 38 trials.

Mechanism of Action: Why Are These Drugs So Successful?

To understand why these numbers keep climbing, it helps to know the biology. GLP-1 (glucagon-like peptide-1) is a hormone released by L-cells in the small intestine after a meal. It has several overlapping functions: it stimulates insulin secretion, slows gastric emptying, and—most importantly for weight loss—acts on receptors in the hypothalamus to reduce appetite and increase feelings of fullness^[3]. Semaglutide, a synthetic GLP-1 analog designed to be resistant to enzymatic breakdown, enhances and sustains these effects far beyond what the body’s natural hormone can achieve.

Tirzepatide adds a second dimension to the equation. It activates not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone, and while its role in weight control has been historically debated, the clinical results of tirzepatide have settled the question: dual agonism provides significantly greater weight loss than GLP-1 agonism alone^[4].

Next-generation agents take this layered strategy even further. Retatrutide is a triple agonist, targeting the GLP-1, GIP, and glucagon receptors simultaneously. Glucagon receptor activation increases energy expenditure and may promote hepatic fat oxidation—in essence, telling the liver to burn more fat^[5]. Amycretin combines GLP-1 receptor agonism with amylin analog activity. Amylin, co-secreted with insulin from pancreatic beta cells, independently slows gastric emptying and suppresses appetite via the area postrema in the brainstem^[6]. By stacking these complementary hormonal pathways, each new generation of drug is gaining access to more of the body’s appetite and metabolic circuitry.

Though uncomfortable, the gastrointestinal side effects are a direct pharmacological consequence of these mechanisms. Delayed gastric emptying causes nausea. Central appetite suppression can lead to a feeling of food aversion. In most patients, these effects diminish over weeks as the body adapts, which is why clinical protocols emphasize a gradual dose escalation.

Implications for Clinical Practice

This review reframes the clinical conversation about obesity in several key ways. First, it provides the strongest evidence to date that pharmacotherapy can deliver weight loss of a magnitude once possible only with surgery. For patients who are not candidates for or prefer to avoid bariatric procedures, these drugs represent a true alternative. Second, the data allow clinicians to compare agents head-to-head in a way that was previously difficult due to the scatter of individual trial results. Semaglutide remains highly effective, but tirzepatide appears to offer a significant advantage, and the multi-agonists in the pipeline suggest the ceiling has not yet been reached.

Important caveats remain. This review focused on adults without diabetes, so the findings may not be directly generalizable to individuals with type 2 diabetes, where weight loss responses can differ. Most trials lasted 12 to 18 months, meaning long-term persistence data—what happens at five or ten years—remains limited. Weight regain after drug discontinuation has been documented in previous studies with semaglutide^[7], raising the question of whether these drugs will need to be used indefinitely. Cost and access remain significant barriers, and the emerging agents like amycretin and retatrutide are not yet approved for clinical use.

Still, the trajectory is unmistakable. Obesity pharmacology has entered an era where 20% or more body weight loss is achievable, reproducible, and, based on current evidence, reasonably safe. For a disease that affects more than 40% of American adults^[8] and drives cardiovascular disease, type 2 diabetes, and certain cancers, this represents a fundamental shift in what medicine has to offer.

Scientific Sources

1. Moiz A, et al. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. Annals of internal medicine. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42673585/
2. Arterburn DE, et al. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020. DOI: 10.1001/jama.2020.12567
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007. DOI: 10.1152/physrev.00034.2006
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. DOI: 10.1056/NEJMc2211120
5. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2301972
6. Lutz TA. Control of energy homeostasis by amylin. Cell Mol Life Sci. 2012. DOI: 10.1007/s00018-011-0905-1
7. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725
8. Hales CM, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief. 2020. PMID: 32487284